Trial Profile
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Sponsors PTC Therapeutics
- 02 Apr 2022 This trial has been completed in France (End Date: 30 Aug 2011) according to European Clinical Trials Database record.
- 01 Apr 2019 Status changed from suspended to discontinued.
- 01 Apr 2014 New trial record